Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-12-22

FDA Approved: PROCYSBI — Supplemental Application (Horizon Therapeutics USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for PROCYSBI (cysteamine bitartrate) submitted by Horizon Therapeutics USA, expanding or updating the product’s labe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Procysbi (mercaptamine bitartrate)

Snippet

SUPPL AP for PROCYSBI (CYSTEAMINE BITARTRATE)